Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
Evogene Ltd. - Ordinary Shares (EVGN)
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
evogene.com/investor-relations
Company Research
Source: PR Newswire
LAV321demonstrated strong results in its third consecutive year of field trials in Europe REHOVOT, Israel, Nov. 19, 2024 /PRNewswire/ -- Lavie Bio Ltd., a leading ag-biologicals company and subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced significant progress in the development of its LAV321 bio-fungicide, targeting downy mildew. Over three years of field trials across Europe, evaluating the efficacy of LAV321 in protecting crops from fungal diseases, LAV321 demonstrated an impressive average efficacy rate of 70% against downy mildew in grapes. These results lead to the decision to advance it to the last stage of product development toward commercialization. Downy mildew is a damaging foliar disease of grapes, leading to yield losses of up to 75% in key growing areas[1]. The global fungicide market, valued at over $24.5 billion in 2024, is projected to grow to $33.27 billion by 2028, with a compound annual growth rate (CAGR) of 7.9%[2]. As public interest in e
Show less
Read more
Impact Snapshot
Event Time:
EVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVGN alerts
High impacting Evogene Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
EVGN
News
- Evogene Reports Third Quarter 2024 Financial ResultsPR Newswire
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results [Yahoo! Finance]Yahoo! Finance
- Evogene Ltd. (NASDAQ: EVGN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field TrialsPR Newswire
- Evogene Ltd. (NASDAQ: EVGN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
EVGN
Earnings
- 3/7/24 - Beat
EVGN
Sec Filings
- 11/21/24 - Form 424B3
- 11/21/24 - Form 6-K
- 10/15/24 - Form SC
- EVGN's page on the SEC website